ASCVD Initiative

The American Heart Association® (AHA) is leading an initiative to educate professionals through an integrated system of care approach and to improve ASCVD management with the development and adherence to quality performance measures. 

The National Integrated ASCVD Management Initiative aims to understand and improve the patient journey by identifying lipid management best practices that can be leveraged nationally across care settings. Our Secondary Prevention goals are to:

  • Improve clinical pathways and processes to impact patient outcomes across care settings within the health system.
  • Increase compliance rates among healthcare providers for guideline-directed medical therapies (GDMT) for ASCVD utilized across care settings within the health system.
Through continuous quality improvement, the ASCVD Initiative and its participants are working diligently to tackle the barriers surrounding ASCVD patient care and provide a framework for quality lipid management nationally. 


Novartis is proud to support the American Heart Association’s Integrated ASCVD Management Initiative.